Adynxx, Inc. (ADYX)

Market Cap	581.00 +9,583.3%
Revenue (ttm)	n/a
Net Income	-10.57M
EPS	-1.82
Shares Out	5.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0401
Beta	-40.82
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADYX

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error